Thymosin β4 sustained release from poly(lactide-co-glycolide) microspheres: Synthesis and implications for treatment of myocardial ischemia

Annals of the New York Academy of Sciences

Volumn 1270, Issue 1, 2012, Pages 112-119

  Thatcher, Jeffrey E ^a,b   Welch, Tré ^a   Eberhart, Robert C ^a,b   Schelly, Zoltan A ^b   Michael Dimaio, J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

Author keywords

Controlled; Heart; Microsphere; Release; Sustained; Thymosin 4

Indexed keywords

ALGINIC ACID; CHITOSAN; COLLAGEN; GELATIN; HEPARIN; MATRIX METALLOPROTEINASE; MICROSPHERE; ORGANIC SOLVENT; POLYGLACTIN; THYMOSIN BETA4;

ARTICLE; BOLUS INJECTION; CLINICAL EFFECTIVENESS; CONTROLLED RELEASE FORMULATION; DEGRADATION; DISSOLUTION; DOSE RESPONSE; DRUG RELEASE; ENCAPSULATION; HEART MUSCLE ISCHEMIA; NONHUMAN; POLYMERIZATION; ROOM TEMPERATURE; SUSTAINED RELEASE FORMULATION; SYNTHESIS;

EID: 84867362005     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06681.x     Document Type: Article

References (59)

1. Aiello, L.P., R.L. Avery, P.G. Arrigg, et al. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331: 1480-1487.
2. Cooper, L.T., Jr., W.R. Hiatt, M.A. Creager, et al. 2001. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc. Med. 6: 235-239.
3. Jain, R.K., A.V. Finn, F.D. Kolodgie, et al. 2007. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat. Clin. Pract. Cardiovasc. Med. 4: 491-502.
4. Lucerna, M., A. Zernecke, R. de Nooijer, et al. 2007. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. Blood 109: 122-129.
5. Virmani, R., F.D. Kolodgie, A.P. Burke, et al. 2005. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler. Thromb. Vasc. Biol. 25: 2054-2061.
6. Laham, R.J., M. Post, M. Rezaee, et al. 2005. Transendocardial and transepicardial intramyocardial fibroblast growth factor-2 administration: myocardial and tissue distribution. Drug Metab. Dispos. 33: 1101-1107.
7. Lazarous, D.F., M. Shou, J.A. Stiber, et al. 1997. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res. 36: 78-85.
8. Fuchs, S., L.F. Satler, R. Kornowski, et al. 2003. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J. Am. Coll. Cardiol. 41: 1721-1724.
9. Bock-Marquette, I., A. Saxena, M.D. White, et al. 2004. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432: 466-472.
10. Bock-Marquette, I., S. Shrivastava, G.C. Pipes, et al. 2009. Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo. J. Mol. Cell Cardiol. 46: 728-738.
11. Mani, K. & R.N. Kitsis. 2003. Myocyte apoptosis: programming ventricular remodeling. J. Am. Coll. Cardiol. 41: 761-764.
12. Sun, Y., J.Q. Zhang, J. Zhang & S. Lamparter. 2000. Cardiac remodeling by fibrous tissue after infarction in rats. J. Lab. Clin. Med. 135: 316-323.
13. Smart, N., C.A. Risebro, J.E. Clark, et al. 2010. Thymosin beta4 facilitates epicardial neovascularization of the injured adult heart. Ann. N. Y. Acad. Sci. 1194: 97-104.
14. Morris, D.C., M. Chopp, L. Zhang, et al. 2010. Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience 169: 674-682.
15. Mora, C.A., C.A. Baumann, J.E. Paino, et al. 1997. Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice. Int. J. Immunopharmacol. 19: 1-8.
16. Grossman, P.M., Z. Han, M. Palasis, et al. 2002. Incomplete retention after direct myocardial injection. Catheter Cardiovasc. Interv. 55: 392-397.
17. Gleason, J.D., K.P. Nguyen, K.V. Kissinger, et al. 2002. Myocardial drug distribution pattern following intrapericardial delivery: an MRI analysis. J. Cardiovasc. Magn. Reson. 4: 311-316.
18. Laham, R.J., M. Rezaee, M. Post, et al. 2003. Intrapericardial administration of basic fibroblast growth factor: myocardial and tissue distribution and comparison with intracoronary and intravenous administration. Catheter Cardiovasc. Interv. 58: 375-381.
19. Kraehenbuehl, T.P., L.S. Ferreira, P. Zammaretti, et al. 2009. Cell-responsive hydrogel for encapsulation of vascular cells. Biomaterials 30: 4318-4324.
20. Chiu, L.L.Y. & M. Radisic. 2011. Controlled-release of thymosin beta 4 using collagen-chitosan composite hydrogels promotes epicardial cell migration and angiogenesis. J. Control. Release 155: 376-385.
21. Iwakura, A., M. Fujita, K. Kataoka, et al. 2003. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels 18: 93-99.
22. Liu, Y., L. Sun, Y. Huan, et al. 2006. Effects of basic fibroblast growth factor microspheres on angiogenesis in ischemic myocardium and cardiac function: analysis with dobutamine cardiovascular magnetic resonance tagging. Eur. J. Cardiothorac. Surg. 30: 103-107.
23. Wei, H.J., H.H. Yang, C.H. Chen, et al. 2007. Gelatin microspheres encapsulated with a nonpeptide angiogenic agent, ginsenoside Rg1, for intramyocardial injection in a rat model with infarcted myocardium. J. Control Release 120: 27-34.
24. Yamamoto, T., N. Suto, T. Okubo, et al. 2001. Intramyocardial delivery of basic fibroblast growth factor-impregnated gelatin hydrogel microspheres enhances collateral circulation to infarcted canine myocardium. Jpn Circ. J. 65: 439-444.
25. Hsieh, P.C., M.E. Davis, J. Gannon, et al. 2006. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J. Clin. Invest. 116: 237-248.
26. Hao, X., E.A. Silva, A. Mansson-Broberg, et al. 2007. Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc. Res. 75: 178-185.
27. Laham, R.J., F.W. Sellke, E.R. Edelman, et al. 1999. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100: 1865-1871.
28. Jain, R.A. 2000. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21: 2475-2490.
29. Alonso, M.J., S. Cohen, T.G. Park, et al. 1993. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm. Res. 10: 945-953.
30. Schwendeman, S.P., H.R. Costantino, R.K. Gupta, et al. 1996. Strategies for stabilising tetanus toxoid towards the development of a single-dose tetanus vaccine. Dev. Biol. Stand. 87: 293-306.
31. Camarata, P.J., R. Suryanarayanan, D.A. Turner, et al. 1992. Sustained release of nerve growth factor from biodegradable polymer microspheres. Neurosurgery 30: 313-319.
32. Cleland, J.L., E.T. Duenas, A. Park, et al. 2001. Development of poly-(D, L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J. Control Release 72: 13-24.
33. Kostanski, J.W., B.A. Dani, B. Schrier & P.P. DeLuca. 2000. Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats. Pharm. Res. 17: 445-450.
34. Okada, H., Y. Doken, Y. Ogawa & H. Toguchi. 1994. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm. Res. 11: 1143-1147.
35. Athanasiou, K.A., G.G. Niederauer & C.M. Agrawal. 1996. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 17: 93-102.
36. Fournier, E., C. Passirani, C.N. Montero-Menei & J.P. Benoit. 2003. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 24: 3311-3331.
37. Ratner, B. & A. Hoffman. 2004. Biomaterials Science: An Introduction to Materials in Medicine. 2nd ed. Elsevier Inc. San Diego, California.
38. Carrascosa, C., I. Torres-Aleman, C. Lopez-Lopez, et al. 2004. Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration. Biomaterials 25: 707-714.
39. Cho, K.Y., S.H. Choi, C.H. Kim, et al. 2001. Protein release microparticles based on the blend of poly(D, L-lactic-co-glycolic acid) and oligo-ethylene glycol grafted poly(L-lactide). J. Control Release 76: 275-284.
40. Ehtezazi, T., C. Washington & C.D. Melia. 1999. Determination of the internal morphology of poly (D, L-lactide) microspheres using stereological methods. J. Control Release 57: 301-314.
41. Rosa, G.D., R. Iommelli, M.I. La Rotonda, et al. 2000. Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres. J. Control Release 69: 283-295.
42. Ikada, Y. & H. Tsuji. 2000. Biodegradable polyesters for medical and ecological applications. Macromol Rapid Comm. 21: 117-132.
43. Kim, H.K. & T.G. Park. 2004. Comparative study on sustained release of human growth hormone from semi-crystalline poly(L-lactic acid) and amorphous poly(D, L-lactic-co-glycolic acid) microspheres: morphological effect on protein release. J. Control Release 98: 115-125.
44. Cui, F., D. Cun, A. Tao, et al. 2005. Preparation and characterization of melittin-loaded poly (DL-lactic acid) or poly(DL-lactic-co-glycolic acid) microspheres made by the double emulsion method. J. Control Release 107: 310-319.
45. Pean, J.M., M.C. Venier-Julienne, F. Boury, et al. 1998. NGF release from poly(D, L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J. Control Release 56: 175-187.
46. Wei, G., G.J. Pettway, L.K. McCauley & P.X. Ma. 2004. The release profiles and bioactivity of parathyroid hormone from poly(lactic-co-glycolic acid) microspheres. Biomaterials 25: 345-352.
47. Diaz, R.V., M. Llabres & C. Evora. 1999. One-month sustained release microspheres of 125I-bovine calcitonin. In vitro-in vivo studies. J. Control Release 59: 55-62.
48. Cleek, R., K. Ting, S.G. Eskin & A. Mikos. 1997. Microparticles of poly(dl-lactic-co-glycolic acid)/poly(ethylene glycol) blends for controlled drug delivery. J. Control Release. 48: 259-268.
49. Ruan, G., S.S. Feng & Q.T. Li. 2002. Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process. J. Control Release 84: 151-160.
50. Ungaro, F., M. Biondi, I. d'Angelo, et al. 2006. Microsphere-integrated collagen scaffolds for tissue engineering: effect of microsphere formulation and scaffold properties on protein release kinetics. J. Control Release 113: 128-136.
51. Wei, G., L.F. Lu & W.Y. Lu. 2007. Stabilization of recombinant human growth hormone against emulsification-induced aggregation by Pluronic surfactants during microencapsulation. Int. J. Pharm. 338: 125-132.
52. Hof, R.P., A. Hof, R. Salzmann & F. Wyler. 1981. Trapping and intramyocardial distribution of microspheres with different diameters in cat and rabbit hearts in vitro. Basic Res. Cardiol. 76: 630-638.
53. Grizzi, I., H. Garreau, S. Li & M. Vert. 1995. Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. Biomaterials 16: 305-311.
54. Vert, M., J. Mauduit & S. Li. 1994. Biodegradation of PLA/GA polymers: increasing complexity. Biomaterials 15: 1209-1213.
55. Shenderova, A., A. Ding & S. Schwendeman. 2004. Potentiometric method for determination of microclimate pH in Poly(lactic-co-glycolic acid) films. Macromolecules 37: 10052-10058.
56. Lucke, A., J. Kiermaier & A. Gopferich. 2002. Peptide acylation by poly(alpha-hydroxy esters). Pharm. Res. 19: 175-181.
57. Sophocleous, A.M., Y. Zhang & S.P. Schwendeman. 2009. A new class of inhibitors of peptide sorption and acylation in PLGA. J. Control Release 137: 179-184.
58. Watson, R.M., D.R. Markle, et al. 1984. Transmural pH gradient in canine myocardial ischemia. Am. J. Physiol. 246: H232-H238.
59. Sun, Y. 2007. Oxidative stress and cardiac repair/remodeling following infarction. Am. J. Med. Sci. 334: 197-205.